-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|February 5, 2024

Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

Experts underscore cost relief of bispecific antibodies via medication assistance programs.

Episodes in this series

Video 1 - "Conditions for Administering Bispecific Therapy"

EP. 1 Conditions for Administering Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 2 Navigating Barriers Which Inhibit Optimal Use of Bispecifics

Video 3 - "Key Decision Makers and Contributors Involved In Bispecific Administration"

EP. 3 Key Decision Makers and Contributors Involved In Bispecific Administration

Video 4 - "Pain Points In Bispecific Operationalization"

EP. 4 Pain Points In Bispecific Operationalization

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 5 Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 6 Optimizing Bispecific Use Through EMR Utilization

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 7 Best Practices For Uptake and Use of Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 8 Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 9 Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 10 Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 11 Protocol For Urgent and Around-the-Clock Bispecific Care

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 12 Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 13 Managed Care Considerations Within Bispecific Landscape

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 14 Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 15 Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

Video 2 - "Navigating Barriers That Inhibit Optimal Use of Bispecifics"

EP. 16 Bispecific Therapies: Current and Future Considerations

The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Experts featured in this series.

Access, Coverage, and Final Reflections on Managing Alzheimer's Disease Agitation

ByKavita Nair, PhD,Anton Porsteinsson , MD,Alireza Atri, MD, PhD

Published: August 10th 2026 | Updated: July 16th 2026

Experts featured in this series.

Choosing Between Approved Therapies: Differentiation, Sequencing, and Black Box Warning Navigation in Alzheimer's Disease Agitation

ByKavita Nair, PhD,Anton Porsteinsson , MD,Alireza Atri, MD, PhD

Published: August 10th 2026 | Updated: July 16th 2026

Experts featured in this series.

Comparing the Two Approved Therapies: Dextromethorphan-Bupropion and Brexpiprazole in Alzheimer's Disease Agitation

ByKavita Nair, PhD,Anton Porsteinsson , MD,Alireza Atri, MD, PhD

Published: August 10th 2026 | Updated: July 16th 2026

Experts featured in this series.

Brexpiprazole and Dextromethorphan-Bupropion: Mechanisms of Action and Key Clinical Trial Data for Approved Alzheimer's Disease Agitation Therapies

ByKavita Nair, PhD,Anton Porsteinsson , MD,Alireza Atri, MD, PhD

Published: August 10th 2026 | Updated: July 16th 2026

Experts featured in this series.

Traditional Pharmacologic Therapies for Alzheimer's Disease Agitation: Mechanisms, Evidence, and Adverse Events

ByKavita Nair, PhD,Anton Porsteinsson , MD,Alireza Atri, MD, PhD

Published: August 10th 2026 | Updated: July 16th 2026

Trending on AJMC

Lipoprotein(a): An FAQ on Awareness, Risk, and Screening Gaps

Gene Therapy for Wet AMD Near an Inflection Point: Arshad Khanani, MD

$20 Billion National Strategy Aims to Close the Women's Health Gap

Senate Unveils Sweeping Bill to Reform 340B Drug Program

Severe Eczema More Than Doubles Shingles Risk